Assessing risk factors for re-bleeding in cirrhotic patients with variceal bleeding
Predictive and Prognostic Significance of Age,Blood Tests,Comorbidities(ABC) Score,Cologne Watch(C-watch)Score and Rockall Score for Risk of Variceal Re-bleeding Among Cirrhotic Patients
This study is trying to see if certain scoring systems can help predict the risk of re-bleeding in people with liver cirrhosis who have experienced variceal bleeding.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06335186 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the predictive and prognostic significance of various scoring systems, including the ABC Score, C-watch Score, and Rockall Score, in assessing the risk of variceal re-bleeding among patients with liver cirrhosis. It will involve a prospective cohort of 100 cirrhotic patients who present with upper gastrointestinal variceal bleeding. Participants will undergo clinical evaluations, laboratory tests, and upper gastrointestinal endoscopy to confirm their condition and assess their risk factors over a one-year study period.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a history of chronic liver disease, impaired liver function, and portal hypertension who present with symptoms of upper gastrointestinal bleeding.
Not a fit: Patients whose upper gastrointestinal bleeding is caused by conditions unrelated to portal hypertension or cirrhosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management strategies for cirrhotic patients at risk of variceal re-bleeding.
How similar studies have performed: While there have been studies assessing risk factors for variceal bleeding, this specific approach using the ABC, C-watch, and Rockall Scores in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patients who met the following inclusion criteria were enrolled:
1. History of chronic liver disease.
2. Impaired liver function.
3. Portal hypertension syndrome (indicated by esophageal varices and/or variceal dilation).
4. Diagnostic imaging confirming liver cirrhosis on ultrasound who admitted to the hospital with symptoms of hematemesis and/or melena underwent clinical and laboratory examinations and an upper gastrointestinal endoscopy and were diagnosed with UGIB due to ruptured esophageal (ESOVs) and/or gastric varices (GASVs).
Exclusion Criteria:
* Exclusion criteria
1. UGIB caused by other cases such as Mallory-Weiss syndrome and esophageal or gastrointestinal ulcers.
2. UGIB due to ruptured veins in conditions other than increased portal pressure like portal hypertension syndrome unrelated to cirrhosis.
3. Patients with portal vein thrombosis.
4. Patients used anticoagulan
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Asmaa S Sayed, resident
- Email: asmaa.sayed@med.sohag.edu.com
- Phone: 01129267396
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.